Aplastic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Aplastic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to compare the absorption of eltrombopag olamine in healthy volunteers to ensure the tablets work the same way for patients with thrombocytopenia or aplastic anemia. https://clinicaltrials.eu/trial/a-study-to-compare-the-absorption-of-eltrombopag-olamine-in-healthy-volunteers-to-ensure-the-tablets-work-the-same-way-for-patients-with-thrombocytopenia-or-aplastic-anemia/ Thu, 30 Apr 2026 13:08:49 +0000 https://clinicaltrials.eu/trial/a-study-to-compare-the-absorption-of-eltrombopag-olamine-in-healthy-volunteers-to-ensure-the-tablets-work-the-same-way-for-patients-with-thrombocytopenia-or-aplastic-anemia/ This study focuses on Thrombocytopenia, a condition where there is a low number of platelets in the blood, and Aplastic anemia, a serious condition where the body stops producing enough new blood cells. The research aims to demonstrate the bioequivalence, or how similarly the body absorbs and uses a medicine, between two different versions of the drug eltrombopag.

Participants will receive eltrombopag in the form of a 75 mg film-coated tablet, which is a pill covered in a thin layer to make it easier to swallow. The study is conducted under fasting conditions, meaning no food is consumed for a certain period before taking the medication. The process involves a crossover design, where individuals receive both the test version and the comparator version of the medication at different times during the study period.

]]> A Study Comparing Eltrombopag Tablets in Healthy Volunteers to Test if Two Forms of the Medicine Work the Same Way in the Body After Taking with Food https://clinicaltrials.eu/trial/a-study-comparing-eltrombopag-tablets-in-healthy-volunteers-to-test-if-two-forms-of-the-medicine-work-the-same-way-in-the-body-after-taking-with-food/ Wed, 29 Apr 2026 15:08:27 +0000 https://clinicaltrials.eu/trial/a-study-comparing-eltrombopag-tablets-in-healthy-volunteers-to-test-if-two-forms-of-the-medicine-work-the-same-way-in-the-body-after-taking-with-food/ This study examines Eltrombopag, a medication used to treat certain blood conditions. The conditions being studied are Aplastic anemia, which is a disorder where the body stops producing enough new blood cells, and Thrombocytopenia, which is a condition characterized by low levels of platelets in the blood. Platelets are small blood cells that help the blood to clot and stop bleeding. The study will use Eltrombopag in the form of film-coated tablets containing 75 milligrams of the active ingredient eltrombopag olamine, which works by stimulating the body to produce more platelets.

The purpose of this study is to compare two different versions of Eltrombopag tablets to see if they work in the same way in the body when taken with food. This is called a bioequivalence study, which means researchers want to confirm that both versions of the medicine are absorbed into the bloodstream at similar rates and amounts. The study will involve healthy volunteers rather than patients with the conditions mentioned, as this is a standard approach for testing whether different versions of a medication behave similarly in the body.

Participants will receive a single dose of each version of the medication on two separate occasions, with a break between doses. They will take the medication after eating a meal, as the study examines how the medicine works under fed conditions. During the study, blood samples will be collected at various times to measure the amount of medication in the bloodstream. The safety of the medication will also be monitored by checking for any unwanted effects, performing heart tracings, measuring vital signs like blood pressure and heart rate, and conducting laboratory tests on blood samples.

]]> Study of REGN7257 for Adults with Severe Aplastic Anemia Unresponsive to or Relapsed After Immunosuppressive Therapy https://clinicaltrials.eu/trial/study-of-regn7257-for-adults-with-severe-aplastic-anemia-unresponsive-to-or-relapsed-after-immunosuppressive-therapy/ Wed, 29 Apr 2026 14:28:23 +0000 https://clinicaltrials.eu/trial/study-of-regn7257-for-adults-with-severe-aplastic-anemia-unresponsive-to-or-relapsed-after-immunosuppressive-therapy/ This clinical trial is focused on studying a condition known as severe aplastic anemia. This is a serious blood disorder where the bone marrow fails to produce enough blood cells. The study is investigating a treatment called REGN7257, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific parts of the immune system. In this case, REGN7257 targets a part of the immune system called the interleukin 2 receptor subunit gamma, which is involved in the body’s immune response.

The purpose of the study is to assess the safety and tolerability of REGN7257 in patients whose severe aplastic anemia has not responded to or has returned after standard immunosuppressive therapy. The study is divided into two parts. In the first part, the focus is on understanding how safe and tolerable the treatment is. In the second part, the study also looks at how effective the treatment is in patients whose condition has relapsed after previous treatments.

Participants in the study will receive REGN7257 through an injection into a vein, a method known as intravenous use. The study will monitor participants for any side effects and measure how their condition responds to the treatment over time. The study aims to provide insights into whether REGN7257 can be a beneficial treatment option for those with severe aplastic anemia who have limited options due to the ineffectiveness of other therapies.

]]>